Agreement part of strategy targeting the
US $7.3 Billion* skincare market in
Mexico
TORONTO,
Nov. 6, 2018 /CNW/
- Khiron Life Sciences Corp. ("Khiron" or
the "Company") (TSXV: KHRN), (OTCQB: KHRNF),
(Frankfurt: A2JMZC), an integrated
medical cannabis company with its core operations in Colombia, announced today that
the Company has extended an agreement with Farmalisto, the regions
leading digital drugstore, to market and distribute the
Company's Kuida® CBD cosmeceutical
brand to a population of over 120 million consumers in Mexico, subject to approvals from the Federal
Commission for the Protection of Health Risks
(COFEPRIS).
Kuida®, the first consumer brand of Khiron's
Wellness unit, brings the benefits of cannabidol (CBD) to a
comprehensive portfolio of skin and body care products for women.
Launched in Colombia in
September 2018 through retail,
wholesale and online channels,
Kuida® will now be available in
Mexico, a significant market
segment with a population of more than 120 Million. Mexico is among the top 10 markets in the
world for cosmetics and personal care products (US Department of
Commerce), and the second largest market for beauty products in
Latin America.
Alvaro Torres, Khiron
Co-founder and CEO stated, "Mexico
is a priority market for Kuida®, where we see
tremendous interest in new innovations in the beauty care market.
As part of our previously announced business strategy to enter the
Mexican market, extending our distribution deal with Farmalisto
allows us to leverage their e-commerce capabilities and network to
connect more women in Mexico with
the Kuida® brand."
Farmalisto is one of Latin
America's leading digital drugstores with more than one
million monthly visits, sustained annual sales growth of 150%, and
a strong presence in Mexico. Led
by CEO and Co-founder Joaquin Mora,
Farmalisto provides customers with innovative products, delivered
with leading commercial technology, provided through the most
innovative digital platform. To see
Kuida® on Farmalisto visit:
https://bit.ly/2AIzd4Z
José Joaquin Mora, CEO
& Co-founder of Farmalisto
stated, "Farmalisto is the largest and most
comprehensive digital health service platform in Mexico. As a pioneer in the pharmaceutical
e-commerce space we are redefining the pharmacy, creating a
simpler, easier and lower cost way of prescribing medications and
health services, at any time, anywhere. With one million
monthly visits and 500,000 orders delivered to date we are the
fastest growing such e-commerce platform in Latin America."
* Source: Mexican Secretariat of Economy (SE), Mexican
Internet Trade Data System (SIAVI).
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. (TSXV: KRHN, OTCQB:
KHRNF, Frankfurt:
A2JMZC) ("Khiron" or the "Company") is positioned to
be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in
Colombia and is fully licensed in
the country for the cultivation, production, domestic distribution,
and international export of both tetrahydrocannabinol (THC) and
cannabidiol (CBD) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
one of the first Colombian based medical cannabis companies to
trade on any exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at www.khiron.ca.
Forward-Looking Statements
This press release may contain certain forward-looking
information and statements ("forward-looking information") within
the meaning of applicable Canadian securities legislation, that are
not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Readers are cautioned to
not place undue reliance on forward-looking information. Actual
results and developments may differ materially from those
contemplated by these statements. Khiron undertakes no obligation
to comment analyses, expectations or statements made by
third-parties in respect of Khiron, its securities, or financial or
operating results (as applicable). Although Khiron believes that
the expectations reflected in forward-looking information in this
press release are reasonable, such forward-looking information has
been based on expectations, factors and assumptions concerning
future events which may prove to be inaccurate and are subject to
numerous risks and uncertainties, certain of which are beyond
Khiron's control, including the risk factors discussed in Khiron's
Filing Statement which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and are made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
SOURCE Khiron Life Sciences Corp.